Australia - Map
Phone: 61 3 9670 3273
Fax: 61 3 9670 3247
Patrys Limited develops natural human antibody therapeutics for the treatment of cancer in Australia. The companys clinical products include PAT-SM6, a natural human antibody used for the treatment of multiple types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers that include multiple myeloma; and PAT-SC1 for treating gastric cancer and solid tumors. It also has late stage preclinical products, such as PAT-LM1, a natural human antibody that is used in the treatment for multiple types of cancer against colon, lung, breast, ovary, and pancreatic cancers. The company was founded in 2006 and is headquartered in Melbourne, Australia.
|Mr. Roger McPherson CPA, GAICD,
Chief Operating Officer
|Dr. James A. Campbell Ph.D., M.B.A.,
Chief Exec. Officer, Managing Director and Director
|Dr. Deanne Greenwood Ph.D., MBA,
VP of Bus. Devel. & Intellectual Property
|Dr. Frank Hensel Ph.D.,
VP of R&D and Managing Director of Patrys GmbH
|Ms. Valentina Dubljevic MBB, BSc ,
VP of Scientific & Clinical Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|